Financhill
Buy
63

TKNO Quote, Financials, Valuation and Earnings

Last price:
$7.33
Seasonality move :
48.29%
Day range:
$5.85 - $6.81
52-week range:
$1.16 - $10.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.89x
P/B ratio:
4.13x
Volume:
1.1M
Avg. volume:
508.9K
1-year change:
244.32%
Market cap:
$340.4M
Revenue:
$37.7M
EPS (TTM):
-$0.59

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
TKNO
Alpha Teknova
$9.4M -- 0.73% -- $11.00
GERN
Geron
$48.5M -$0.04 5681.41% -56% $3.81
NBY
NovaBay Pharmaceuticals
$3M -$0.24 14.03% -95.43% $0.85
PTNT
Internet Patents Corporation
-- -- -- -- --
TOVX
Theriva Biologics
-- -$5.50 -- -8.25% $6.00
ZVRA
Zevra Therapeutics
$17M -$0.18 395.13% -53.57% $21.63
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
TKNO
Alpha Teknova
$6.37 $11.00 $340.4M -- $0.00 0% 7.89x
GERN
Geron
$1.26 $3.81 $802.5M -- $0.00 0% 7.17x
NBY
NovaBay Pharmaceuticals
$0.57 $0.85 $3.3M -- $0.00 0% 0.15x
PTNT
Internet Patents Corporation
-- -- -- -- $0.00 0% --
TOVX
Theriva Biologics
$0.64 $6.00 $1.8M -- $0.00 0% 0.63x
ZVRA
Zevra Therapeutics
$7.79 $21.63 $421.6M -- $0.00 0% 15.26x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
TKNO
Alpha Teknova
14.07% 0.879 3.02% 3.10x
GERN
Geron
30.68% 1.799 11.72% 6.84x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
PTNT
Internet Patents Corporation
-- 0.000 -- --
TOVX
Theriva Biologics
-- -2.512 -- --
ZVRA
Zevra Therapeutics
60% 1.216 13.29% 2.35x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
TKNO
Alpha Teknova
$2.1M -$5.6M -27.37% -31.69% -60.75% -$1.5M
GERN
Geron
$38.4M -$16.7M -35.11% -46.58% -29.38% -$48M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PTNT
Internet Patents Corporation
-- -- -- -- -- --
TOVX
Theriva Biologics
-- -$4.6M -- -- -- -$4.7M
ZVRA
Zevra Therapeutics
$10.7M -$15.4M -102.42% -208.85% -150.91% -$16.3M

Alpha Teknova vs. Competitors

  • Which has Higher Returns TKNO or GERN?

    Geron has a net margin of -61.73% compared to Alpha Teknova's net margin of -50.09%. Alpha Teknova's return on equity of -31.69% beat Geron's return on equity of -46.58%.

    Company Gross Margin Earnings Per Share Invested Capital
    TKNO
    Alpha Teknova
    22.97% -$0.11 $95.9M
    GERN
    Geron
    96.96% -$0.03 $387M
  • What do Analysts Say About TKNO or GERN?

    Alpha Teknova has a consensus price target of $11.00, signalling upside risk potential of 72.69%. On the other hand Geron has an analysts' consensus of $3.81 which suggests that it could grow by 202.58%. Given that Geron has higher upside potential than Alpha Teknova, analysts believe Geron is more attractive than Alpha Teknova.

    Company Buy Ratings Hold Ratings Sell Ratings
    TKNO
    Alpha Teknova
    3 2 0
    GERN
    Geron
    4 3 0
  • Is TKNO or GERN More Risky?

    Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Geron has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.471%.

  • Which is a Better Dividend Stock TKNO or GERN?

    Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TKNO or GERN?

    Alpha Teknova quarterly revenues are $9.3M, which are smaller than Geron quarterly revenues of $39.6M. Alpha Teknova's net income of -$5.7M is higher than Geron's net income of -$19.8M. Notably, Alpha Teknova's price-to-earnings ratio is -- while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 7.89x versus 7.17x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TKNO
    Alpha Teknova
    7.89x -- $9.3M -$5.7M
    GERN
    Geron
    7.17x -- $39.6M -$19.8M
  • Which has Higher Returns TKNO or NBY?

    NovaBay Pharmaceuticals has a net margin of -61.73% compared to Alpha Teknova's net margin of -49.65%. Alpha Teknova's return on equity of -31.69% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    TKNO
    Alpha Teknova
    22.97% -$0.11 $95.9M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About TKNO or NBY?

    Alpha Teknova has a consensus price target of $11.00, signalling upside risk potential of 72.69%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 49.07%. Given that Alpha Teknova has higher upside potential than NovaBay Pharmaceuticals, analysts believe Alpha Teknova is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    TKNO
    Alpha Teknova
    3 2 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is TKNO or NBY More Risky?

    Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock TKNO or NBY?

    Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TKNO or NBY?

    Alpha Teknova quarterly revenues are $9.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Alpha Teknova's net income of -$5.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Alpha Teknova's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 7.89x versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TKNO
    Alpha Teknova
    7.89x -- $9.3M -$5.7M
    NBY
    NovaBay Pharmaceuticals
    0.15x -- $2.4M -$1.2M
  • Which has Higher Returns TKNO or PTNT?

    Internet Patents Corporation has a net margin of -61.73% compared to Alpha Teknova's net margin of --. Alpha Teknova's return on equity of -31.69% beat Internet Patents Corporation's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TKNO
    Alpha Teknova
    22.97% -$0.11 $95.9M
    PTNT
    Internet Patents Corporation
    -- -- --
  • What do Analysts Say About TKNO or PTNT?

    Alpha Teknova has a consensus price target of $11.00, signalling upside risk potential of 72.69%. On the other hand Internet Patents Corporation has an analysts' consensus of -- which suggests that it could fall by --. Given that Alpha Teknova has higher upside potential than Internet Patents Corporation, analysts believe Alpha Teknova is more attractive than Internet Patents Corporation.

    Company Buy Ratings Hold Ratings Sell Ratings
    TKNO
    Alpha Teknova
    3 2 0
    PTNT
    Internet Patents Corporation
    0 0 0
  • Is TKNO or PTNT More Risky?

    Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Internet Patents Corporation has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock TKNO or PTNT?

    Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Internet Patents Corporation offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. Internet Patents Corporation pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TKNO or PTNT?

    Alpha Teknova quarterly revenues are $9.3M, which are larger than Internet Patents Corporation quarterly revenues of --. Alpha Teknova's net income of -$5.7M is higher than Internet Patents Corporation's net income of --. Notably, Alpha Teknova's price-to-earnings ratio is -- while Internet Patents Corporation's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 7.89x versus -- for Internet Patents Corporation. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TKNO
    Alpha Teknova
    7.89x -- $9.3M -$5.7M
    PTNT
    Internet Patents Corporation
    -- -- -- --
  • Which has Higher Returns TKNO or TOVX?

    Theriva Biologics has a net margin of -61.73% compared to Alpha Teknova's net margin of --. Alpha Teknova's return on equity of -31.69% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TKNO
    Alpha Teknova
    22.97% -$0.11 $95.9M
    TOVX
    Theriva Biologics
    -- -$1.60 --
  • What do Analysts Say About TKNO or TOVX?

    Alpha Teknova has a consensus price target of $11.00, signalling upside risk potential of 72.69%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 832.84%. Given that Theriva Biologics has higher upside potential than Alpha Teknova, analysts believe Theriva Biologics is more attractive than Alpha Teknova.

    Company Buy Ratings Hold Ratings Sell Ratings
    TKNO
    Alpha Teknova
    3 2 0
    TOVX
    Theriva Biologics
    0 0 0
  • Is TKNO or TOVX More Risky?

    Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

  • Which is a Better Dividend Stock TKNO or TOVX?

    Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TKNO or TOVX?

    Alpha Teknova quarterly revenues are $9.3M, which are larger than Theriva Biologics quarterly revenues of --. Alpha Teknova's net income of -$5.7M is lower than Theriva Biologics's net income of -$4.4M. Notably, Alpha Teknova's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 7.89x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TKNO
    Alpha Teknova
    7.89x -- $9.3M -$5.7M
    TOVX
    Theriva Biologics
    0.63x -- -- -$4.4M
  • Which has Higher Returns TKNO or ZVRA?

    Zevra Therapeutics has a net margin of -61.73% compared to Alpha Teknova's net margin of -296.76%. Alpha Teknova's return on equity of -31.69% beat Zevra Therapeutics's return on equity of -208.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    TKNO
    Alpha Teknova
    22.97% -$0.11 $95.9M
    ZVRA
    Zevra Therapeutics
    88.66% -$0.69 $99.2M
  • What do Analysts Say About TKNO or ZVRA?

    Alpha Teknova has a consensus price target of $11.00, signalling upside risk potential of 72.69%. On the other hand Zevra Therapeutics has an analysts' consensus of $21.63 which suggests that it could grow by 177.6%. Given that Zevra Therapeutics has higher upside potential than Alpha Teknova, analysts believe Zevra Therapeutics is more attractive than Alpha Teknova.

    Company Buy Ratings Hold Ratings Sell Ratings
    TKNO
    Alpha Teknova
    3 2 0
    ZVRA
    Zevra Therapeutics
    4 0 0
  • Is TKNO or ZVRA More Risky?

    Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.870, suggesting its more volatile than the S&P 500 by 87.041%.

  • Which is a Better Dividend Stock TKNO or ZVRA?

    Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TKNO or ZVRA?

    Alpha Teknova quarterly revenues are $9.3M, which are smaller than Zevra Therapeutics quarterly revenues of $12M. Alpha Teknova's net income of -$5.7M is higher than Zevra Therapeutics's net income of -$35.7M. Notably, Alpha Teknova's price-to-earnings ratio is -- while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 7.89x versus 15.26x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TKNO
    Alpha Teknova
    7.89x -- $9.3M -$5.7M
    ZVRA
    Zevra Therapeutics
    15.26x -- $12M -$35.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is a Millionaire-Maker Stock?
What Is a Millionaire-Maker Stock?

From time to time, investors will run across the term…

5 Investors to Follow Other Than Warren Buffett
5 Investors to Follow Other Than Warren Buffett

There is no doubt that Warren Buffett is one of…

Is BYD a Threat To Tesla Shareholders?
Is BYD a Threat To Tesla Shareholders?

BYD (OTC:BYDDY) has rocketed to the top of China’s booming…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Buy
99
DAVE alert for May 9

Dave [DAVE] is up 7.5% over the past day.

Buy
52
QDEL alert for May 9

QuidelOrtho [QDEL] is down 0.22% over the past day.

Buy
61
TPC alert for May 9

Tutor Perini [TPC] is up 8.37% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock